Newer Cancer Drugs Are Often Less Effective And More Expensive Than Old Ones

Table of contents:

Newer Cancer Drugs Are Often Less Effective And More Expensive Than Old Ones
Newer Cancer Drugs Are Often Less Effective And More Expensive Than Old Ones

Video: Newer Cancer Drugs Are Often Less Effective And More Expensive Than Old Ones

Отличия серверных жестких дисков от десктопных
Video: This could change the way cancer is treated | The Economist 2023, February
Anonim

Newer cancer drugs are often less effective and more expensive than old ones

Many newer cancer drugs provide very little benefit to patients when compared to previous treatments. New drugs rarely match their high price, according to two new studies presented at the European Society for Medical Oncology (ESMO) congress.

Newer cancer drugs are often less effective and more expensive than old ones
Newer cancer drugs are often less effective and more expensive than old ones

Photo: Google Images /

Many newer cancer drugs provide very little benefit to patients when compared to previous treatments. New drugs rarely match their high price, according to two new studies presented at the European Society for Medical Oncology (ESMO) congress.

In studies, scientists have tried to figure out whether drugs developed in the past 10-15 years are giving better results than older drugs (standard treatment). Patient survival, quality of life and side effects were compared with different treatment regimens.

“Most of the new cancer drugs had few additional benefits, so patients and doctors should not assume that a drug is better just because it’s new,” said Marc Rodwin of the University of Suffolk, co-author of a study on cancer drugs developed in France.

In the study, nearly half of new drugs approved in Europe from 2004 to 2017 for the treatment of solid tumors had low scores on the ESMO-MCBS Additive Value Scale, and two-thirds had similarly low scores on the ESMO-MCBS scale. used by French regulators. On average, treatment with a new drug in Europe costs € 2,525 more per month than with older drugs.

In the second study, published in the Journal of Clinical Oncology, scientists analyzed drugs approved for the treatment of solid tumors in adults in the United States and Europe from 2009 to 2017. The scientists did not find a link between the price and the clinical value of the drugs, which they also examined on several special scales. The average cost of treatment with drugs with low efficacy rates was $ 12,436 per month in the US and $ 4361-5273 in the EU.

“Drug prices were not associated with clinical benefit in all the countries we tested. For example, some of the more expensive lung and prostate cancer drugs in Switzerland have lower ESMO-MCBS scores than their cheaper competitors,”says Professor Kerstin Vokinger of the University of Zurich.

Scientists believe that doctors should carefully evaluate the effectiveness of anti-cancer drugs before prescribing them and remind that older drugs may be more effective than new ones.

Popular by topic